The US Food and Drug Administration has approved ustekinumab-aauz (Otulfi), a biosimilar that references Johnson & Johnson’s ustekinumab (Stelara). This is the fourth ustekinumab biosimilar approved in the United States. Like the reference product, ustekinumab-aauz is indicated for: Patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or ...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
